# A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma

> **NCT01123785** · PHASE1,PHASE2 · COMPLETED · sponsor: **Inotek Pharmaceuticals Corporation** · enrollment: 144 (actual)

## Conditions studied

- Glaucoma
- Ocular Hypertension

## Interventions

- **DRUG:** INO-8875
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01123785
- **Lead sponsor:** Inotek Pharmaceuticals Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2011-12
- **Final completion:** 2012-01
- **Target enrollment:** 144 (ACTUAL)
- **Last updated:** 2012-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01123785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01123785, "A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT01123785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*